Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged

• MD
  Minnesota Department of Health
• OS
  Ohio State University
• NC
  Nationwide Children's Hospital
• DU
  Drexel University
• CF
  Centers for Disease Control and Prevention
• CO
  College of Medicine, Drexel University
• NC
  National Center for Chronic Disease Prevention and Health Promotion
• NC
  National Center for Immunization and Respiratory Diseases